JMJD2A Promotes Cellular Transformation by Blocking Cellular Senescence through Transcriptional Repression of the Tumor Suppressor CHD5

Cell Reports

Volumn 2, Issue 5, 2012, Pages 1233-1243

  Mallette, Frédérick A ^a,b,d   Richard, Stéphane ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMODOMAIN HELICASE DNA BINDING DOMAIN 5; HELICASE; JMJD2A PROTEIN; OXYGENASE; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL AGING; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FIBROBLAST; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MOUSE; NONHUMAN; ONCOGENE K RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROMOTER REGION; SENESCENCE;

ALLELES; ANIMALS; CELL AGING; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN IMMUNOPRECIPITATION; DNA HELICASES; G1 PHASE CELL CYCLE CHECKPOINTS; HEK293 CELLS; HELA CELLS; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MCF-7 CELLS; MICE; NERVE TISSUE PROTEINS; RAS PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84870463217     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.09.033     Document Type: Article

References (59)

1. Bagchi A., Papazoglu C., Wu Y., Capurso D., Brodt M., Francis D., Bredel M., Vogel H., Mills A.A. CHD5 is a tumor suppressor at human 1p36. Cell 2007, 128:459-475.
2. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
3. Bello M.J., Leone P.E., Vaquero J., de Campos J.M., Kusak M.E., Sarasa J.L., Pestaña A., Rey J.A. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int. J. Cancer 1995, 64:207-210.
4. Bièche I., Champème M.H., Matifas F., Cropp C.S., Callahan R., Lidereau R. Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res. 1993, 53:1990-1994.
5. Black J.C., Allen A., Van Rechem C., Forbes E., Longworth M., Tschöp K., Rinehart C., Quiton J., Walsh R., Smallwood A., et al. Conserved antagonism between JMJD2A/KDM4A and HP1γ during cell cycle progression. Mol. Cell 2010, 40:736-748.
6. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A.H., Schlegelberger B., Stein H., Dörken B., Jenuwein T., Schmitt C.A. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665.
7. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
8. Cloos P.A., Christensen J., Agger K., Maiolica A., Rappsilber J., Antal T., Hansen K.H., Helin K. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006, 442:307-311.
9. Colicelli J. Human RAS superfamily proteins and related GTPases. Sci. STKE 2004, 2004:RE13.
10. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benguría A., Zaballos A., Flores J.M., Barbacid M., et al. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642.
11. Courtois-Cox S., Genther Williams S.M., Reczek E.E., Johnson B.W., McGillicuddy L.T., Johannessen C.M., Hollstein P.E., MacCollin M., Cichowski K. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006, 10:459-472.
12. de Stanchina E., Querido E., Narita M., Davuluri R.V., Pandolfi P.P., Ferbeyre G., Lowe S.W. PML is a direct p53 target that modulates p53 effector functions. Mol. Cell 2004, 13:523-535.
13. Delgado M.D., Vaqué J.P., Arozarena I., López-Ilasaca M.A., Martínez C., Crespo P., León J. H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism. Oncogene 2000, 19:783-790.
14. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre' M., Nuciforo P.G., Bensimon A., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
15. Ehrbrecht A., Müller U., Wolter M., Hoischen A., Koch A., Radlwimmer B., Actor B., Mincheva A., Pietsch T., Lichter P., et al. Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J. Pathol. 2006, 208:554-563.
16. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
17. Ewald J.A., Desotelle J.A., Wilding G., Jarrard D.F. Therapy-induced senescence in cancer. J. Natl. Cancer Inst. 2010, 102:1536-1546.
18. Ferbeyre G., de Stanchina E., Querido E., Baptiste N., Prives C., Lowe S.W. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 2000, 14:2015-2027.
19. Ferbeyre G., de Stanchina E., Lin A.W., Querido E., McCurrach M.E., Hannon G.J., Lowe S.W. Oncogenic ras and p53 cooperate to induce cellular senescence. Mol. Cell. Biol. 2002, 22:3497-3508.
20. Gray S.G., Iglesias A.H., Lizcano F., Villanueva R., Camelo S., Jingu H., Teh B.T., Koibuchi N., Chin W.W., Kokkotou E., Dangond F. Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein. J. Biol. Chem. 2005, 280:28507-28518.
21. Huang Y., Fang J., Bedford M.T., Zhang Y., Xu R.M. Recognition of histone H3 lysine-4 methylation by the double tudor domain of JMJD2A. Science 2006, 312:748-751.
22. Jacobs J.J., Kieboom K., Marino S., DePinho R.A., van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397:164-168.
23. Jacobs J.J., Keblusek P., Robanus-Maandag E., Kristel P., Lingbeek M., Nederlof P.M., van Welsem T., van de Vijver M.J., Koh E.Y., Daley G.Q., van Lohuizen M. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat. Genet. 2000, 26:291-299.
24. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001, 410:1111-1116.
25. Kiaris H., Spandidos D. Mutations of ras genes in human tumors (review). Int. J. Oncol. 1995, 7:413-421.
26. Kim T.D., Shin S., Berry W.L., Oh S., Janknecht R. The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. J. Cell. Biochem. 2012, 113:1368-1376.
27. Klose R.J., Yamane K., Bae Y., Zhang D., Erdjument-Bromage H., Tempst P., Wong J., Zhang Y. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature 2006, 442:312-316.
28. Kortlever R.M., Higgins P.J., Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat. Cell Biol. 2006, 8:877-884.
29. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
30. Lee J., Thompson J.R., Botuyan M.V., Mer G. Distinct binding modes specify the recognition of methylated histones H3K4 and H4K20 by JMJD2A-tudor. Nat. Struct. Mol. Biol. 2008, 15:109-111.
31. Li B.X., Zhang M.C., Luo C.L., Yang P., Li H., Xu H.M., Xu H.F., Shen Y.W., Xue A.M., Zhao Z.Q. Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro. J. Exp. Clin. Cancer Res. 2011, 30:90.
32. Lin H.K., Chen Z., Wang G., Nardella C., Lee S.W., Chan C.H., Yang W.L., Wang J., Egia A., Nakayama K.I., et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010, 464:374-379.
33. Liu G., Bollig-Fischer A., Kreike B., van de Vijver M.J., Abrams J., Ethier S.P., Yang Z.Q. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 2009, 28:4491-4500.
34. Mallette F.A., Ferbeyre G. The DNA damage signaling pathway connects oncogenic stress to cellular senescence. Cell Cycle 2007, 6:1831-1836.
35. Mallette F.A., Gaumont-Leclerc M.F., Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev. 2007, 21:43-48.
36. Mallette F.A., Mattiroli F., Cui G., Young L.C., Hendzel M.J., Mer G., Sixma T.K., Richard S. RNF8- and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J. 2012, 31:1865-1878.
37. Marfella C.G., Imbalzano A.N. The Chd family of chromatin remodelers. Mutat. Res. 2007, 618:30-40.
38. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
39. Nardella C., Clohessy J.G., Alimonti A., Pandolfi P.P. Pro-senescence therapy for cancer treatment. Nat. Rev. Cancer 2011, 11:503-511.
40. Narita M., Nunez S., Heard E., Narita M., Lin A.W., Hearn S.A., Spector D.L., Hannon G.J., Lowe S.W. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113:703-716.
41. Narita M., Narita M., Krizhanovsky V., Nuñez S., Chicas A., Hearn S.A., Myers M.P., Lowe S.W. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 2006, 126:503-514.
42. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., Higashimoto Y., Appella E., Minucci S., Pandolfi P.P., Pelicci P.G. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000, 406:207-210.
43. Peeper D.S., Shvarts A., Brummelkamp T., Douma S., Koh E.Y., Daley G.Q., Bernards R. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat. Cell Biol. 2002, 4:148-153.
44. Rowland B.D., Bernards R., Peeper D.S. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat. Cell Biol. 2005, 7:1074-1082.
45. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., Lowe S.W. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109:335-346.
46. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 2007, 7:295-308.
47. Seger Y.R., García-Cao M., Piccinin S., Cunsolo C.L., Doglioni C., Blasco M.A., Hannon G.J., Maestro R. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2002, 2:401-413.
48. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
49. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91:325-334.
50. Tsukada Y., Fang J., Erdjument-Bromage H., Warren M.E., Borchers C.H., Tempst P., Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006, 439:811-816.
51. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
52. Weber J.D., Taylor L.J., Roussel M.F., Sherr C.J., Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat. Cell Biol. 1999, 1:20-26.
53. Whetstine J.R., Nottke A., Lan F., Huarte M., Smolikov S., Chen Z., Spooner E., Li E., Zhang G., Colaiacovo M., Shi Y. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 2006, 125:467-481.
54. White P.S., Maris J.M., Beltinger C., Sulman E., Marshall H.N., Fujimori M., Kaufman B.A., Biegel J.A., Allen C., Hilliard C., et al. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc. Natl. Acad. Sci. USA 1995, 92:5520-5524.
55. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
56. Yang Z.Q., Imoto I., Fukuda Y., Pimkhaokham A., Shimada Y., Imamura M., Sugano S., Nakamura Y., Inazawa J. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res. 2000, 60:4735-4739.
57. Yeang C.H., McCormick F., Levine A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J. 2008, 22:2605-2622.
58. Zhang D., Yoon H.G., Wong J. JMJD2A is a novel N-CoR-interacting protein and is involved in repression of the human transcription factor achaete scute-like homologue 2 (ASCL2/Hash2). Mol. Cell. Biol. 2005, 25:6404-6414.
59. Zhao R., Yan Q., Lv J., Huang H., Zheng W., Zhang B., Ma W. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer 2012, 76:324-331.